Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

This study is testing a combination of two drugs — adebrelimab (an immunotherapy) and fuzuloparib (a PARP inhibitor that targets DNA repair) — in women with ovarian cancer that has come back within 6 months after platinum-based chemotherapy, a situation called platinum-resistant recurrence. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Your cancer returned within 6 months after your last platinum chemotherapy - Your tumor has a mutation in HRR genes (genes involved in DNA repair), confirmed by a tissue or blood test - You have at least one measurable tumor on imaging - Your performance status is ECOG 0–1 **You may NOT be eligible if...** - Your cancer did not return within 6 months of platinum treatment - You do not have an HRR gene mutation - You have already had more than a certain number of prior treatment lines Talk to your doctor to see if this trial is right for you.